Melane Sampson, Author at BioTuesdays

Developments

cbdMD acquires Bluebird Botanicals

cbdMD (NYSE American: YCBD) has announced the strategic acquisition of closely held Bluebird Botanicals through an asset purchase comprised of an initial share issuance and earnout shares. According to cbdMD, the...

January 14, 2026

Developments

Clearmind achieves 100% treatment success in second cohort of CMND-100 trial in AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100—the...

January 14, 2026

Executive Moves

Oncolytics names John McAdory EVP strategy and operations; Yujun Wu VP biostatistics

Oncolytics Biotech (NASDAQ: ONCY) has announced the appointments of John McAdory as executive vice president (EVP), strategy and operations, and Yujun Wu as vice president (VP), head of biostatistics. According to...

January 14, 2026

Feature

In conversation with Leslie Loveless, CEO and managing partner of Slone Partners

For more than two decades, Slone Partners has maintained a dedicated focus on leadership recruitment for life sciences and healthcare organizations. The company’s co-CEO and managing partner, Leslie Loveless, has been...

January 13, 2026

Developments

Profound surpasses 2025 TULSA-PRO installed base goal

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that its TULSA-PRO system installed base reached 78 as of December 31, 2025—exceeding its previously announced goal of 75 installs by year-end 2025. The company’s TULSA...

January 12, 2026

Developments

Nature Eye publishes positive Phase 1 results for Ocugen’s gene therapy

Ocugen (NASDAQ: OCGN) has announced the publication of positive Phase 1 GARDian1 trial results for OCU410ST, its novel modifier gene therapy for Stargardt disease, in the peer-reviewed journal Nature Eye, published by...

January 12, 2026

Executive Moves

Achieve appoints Dr. Mark Rubenstein as CMO

Achieve Life Sciences (NASDAQ: ACHV) has announced the promotion of Mark Rubenstein, MD, from interim chief medical officer (CMO) to CMO. Dr. Rubinstein brings more than two decades of experience in clinical medicine...

January 12, 2026

Uncategorized

Lantern launches AI center in India to industrialize RADR

Lantern Pharma (NASDAQ: LTRN) has announced the establishment of the AI Center of Excellence and Advanced Agentic Labs in Bengaluru, India, to industrialize its proprietary RADR AI platform, which integrates hundreds of...

January 12, 2026

Developments

PharmaJet’s Needle-free Injection System selected for DNA immunotherapy in advanced melanoma

Closely held PharmaJet announced that its partner, Scancell, has reported updated Phase 2 clinical data from the SCOPE study in unresectable advanced melanoma demonstrating a progression-free survival (PFS) rate of 74%...

January 9, 2026

Developments

Autonomix highlights data showing pain relief observed in all stages of pancreatic cancer

Autonomix Medical (NASDAQ: AMIX) has announced new subgroup clinical data from its proof-of-concept study presented at the 2026 ASCO Gastrointestinal Cancers Symposium demonstrating rapid, durable, and meaningful pain...

January 9, 2026

Author - Melane Sampson

cbdMD acquires Bluebird Botanicals

Clearmind achieves 100% treatment success in second cohort of CMND-100 trial in AUD

Oncolytics names John McAdory EVP strategy and operations; Yujun Wu VP biostatistics

In conversation with Leslie Loveless, CEO and managing partner of Slone Partners

Profound surpasses 2025 TULSA-PRO installed base goal

Nature Eye publishes positive Phase 1 results for Ocugen’s gene therapy

Achieve appoints Dr. Mark Rubenstein as CMO

Lantern launches AI center in India to industrialize RADR

PharmaJet’s Needle-free Injection System selected for DNA immunotherapy in advanced melanoma

Autonomix highlights data showing pain relief observed in all stages of pancreatic cancer

Subscribe